How much funding has ImmuneOncia Therapeutics raised?

ImmuneOncia Therapeutics has raised $51.0M in total funding, most recently a Series B round.

Who are ImmuneOncia Therapeutics's investors?

ImmuneOncia Therapeutics's investors include Paratus Investment, Premier Inc..

When was ImmuneOncia Therapeutics founded?

ImmuneOncia Therapeutics was founded in 2016.

Where is ImmuneOncia Therapeutics headquartered?

ImmuneOncia Therapeutics is headquartered in Seoul, South Korea.

What industry is ImmuneOncia Therapeutics in?

ImmuneOncia Therapeutics operates in Biotech, Healthcare.

How many employees does ImmuneOncia Therapeutics have?

ImmuneOncia Therapeutics has 11-50 employees.

ImmuneOncia Therapeutics

IPO

Changing the Standard of cancer treatment by bringing Korea's 1st immuno-oncology drug

Seoul, South Korea · Founded 2016 · $51.0M raised

Biotech

Healthcare

Headquarters: Seoul
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: immuneoncia.com
Total Funding: $51.0M
Last Round: $18.0M Series BJan 2021
Rounds: 2

About

ImmuneOncia Therapeutics is a South Korean immuno-oncology biopharmaceutical company focused on developing novel immunotherapies for cancer patients worldwide. Founded in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company leverages expertise in antibody engineering and drug development to create immune checkpoint inhibitors and combination therapies. Its lead asset IMC-001 (danburstotug), a PD-L1 antibody, has shown strong clinical results including three-year survival rates above 80% in perioperative settings across gastric, esophageal, and liver cancers. The company publicly listed on KOSDAQ in 2025.

Summary

ImmuneOncia Therapeutics is a Biotech company based in Seoul, South Korea, founded in 2016. It has raised $51.0M in total across 2 rounds, most recently a $18.0M Series B round in Jan 2021. Investors include Paratus Investment and Premier Inc..